Clinical Trial Update: Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/Phase 2 clinical trial results for Tagraxofusp in Blastic Plasmacytoid Dendritic Cell Neoplasm and Acute Myeloid Leukemia have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Blastic Plasmacytoid Dendritic Cell Neoplasm

Drugs mentioned

• Tagraxofusp (tagraxofusp)

Snippet

Sponsor: Stemline Therapeutics, Inc. | Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Acute Myeloid Leukemia (AML) | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-08-01